<a href="https://www.fiercebiotech.com/biotech/biogen-axes-denali-partnered-parkinsons-prospect-after-phase-2-flop" hreflang="en">Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop</a>
Biogen has terminated the development of its Parkinson's disease candidate, BIIB122 (DNL151), after a phase 2b trial failed to meet its primary endpoint, despite showing evidence of target activity. Denali Therapeutics will continue testing the drug independently in a separate phase 2a trial focused on LRRK2-associated Parkinson's.
The most valuable insight for you is the strategic decision by Denali Therapeutics to continue independently testing its small molecule targeting LRRK2-associated Parkinson’s despite the phase 2b trial's failure. This reflects an ongoing belief in the potential for LRRK2 inhibition, highlighting an opportunity to monitor Denali's upcoming phase 2a trial outcomes. This persistence could signal a differentiated approach to Parkinson’s that remains promising, especially in the context of precision medicine and the specific genetic subpopulations they aim to target.